slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
278,311-278,340 of 319,975
09
The slide uses a split-screen layout to contrast clinical challenges with the specific reasons for treatment switching.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · Problem1 hit
10
Includes a line chart showing treatment duration and a pie chart showing patient outcomes.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · Problem1 hit
11
Includes scatter plot for MMR correlation and bar chart for therapeutic index comparison.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · Problem1 hit
12
The slide outlines three strategic pillars (Drive Deeper Responses, Improve Tolerability, Enhance Safety & Convenience) and maps them to specific clinical development programs.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · Problem1 hit
13
Uses a before-after-bridge structure to contrast market limitations with product advantages.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · Problem1 hit
14
The chart uses a broken axis to represent the significantly larger patient population for HER2 overexpressing cancers compared to mutations.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · Problem1 hit
15
The chart uses a logarithmic scale for selectivity. The right side provides a qualitative critique of competitor molecules.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · Problem1 hit
16
Includes a list of abbreviations at the bottom.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · Problem1 hit
17
Imara | Mergers and Acquisitions Presentation Deck | 45 slidesImara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · Problem1 hit
18
Includes a stylized chemical structure graphic.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · Problem1 hit
19
Includes a timeline of key drug approvals and a survival probability chart.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · Problem1 hit
20
The slide uses a split-screen layout to contrast clinical challenges with the rationale for treatment switching.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
21
The slide uses a comparative table to frame the problem of current drug limitations, setting up a solution-oriented conclusion.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
22
Includes clinical trial data and resistance mutation analysis.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
23
The slide uses a split-screen layout to contrast current market realities with the company's vision, supported by a survival curve and a patient outcome pie chart.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
24
The slide uses a custom table structure to show competitive positioning of ELVN-001 against existing TKI generations.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
25
The slide outlines the strategic positioning of a drug candidate (ELVN-001) by contrasting its desired profile against current standards of care.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
26
Includes structural biology diagrams of BCR-ABL protein domains and a table comparing binding conformations.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
27
The table highlights key differentiators such as lower BCRP substrate status and improved plasma protein binding for ELVN-001.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
28
Includes both a competitive cellular phosphorylation table and a specific kinase selectivity table for ELVN-001.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
29
The slide uses a scatter plot for efficacy correlation and a bar chart for safety margin comparison.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank Beat · SolutionLoop · Cost Of Inaction1 hit
30
The slide uses a process-oriented layout to show the progression of clinical trials.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
31
Features a stylized chemical structure graphic.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
32
Uses a before-after framing to contrast market limitations with product solution.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
33
The chart uses a broken axis to represent the significantly larger patient population for HER2 overexpressing cancers compared to the initial focus areas.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
34
The slide contrasts established therapies with investigational ones, emphasizing the lack of selective TKIs and the resulting toxicity issues.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
35
The slide highlights a gap in the market for a selective, irreversible TKI for brain metastases.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
36
Includes a list of abbreviations at the bottom.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
37
The table uses a heatmap-style color coding (green for favorable, red for unfavorable) to visualize potency differences.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit
38
The table highlights ELVN-002's superior selectivity (sparing EGFR) and better pharmacokinetic properties compared to competitors.Imara | Mergers and Acquisitions Presentation Deck | 45 slides · Enliven Therapeutics / Imara
Press release Investment bank 1 hit